Abstract
Despite increasing prevalence of T1D in ethnic minorities, they remain underrepresented in research studies evaluating diabetes technologies. Experiences of diverse cohorts are essential to assessing acceptability of diabetes devices. The Control-IQ Observational (CLIO) Study is an ongoing prospective, real-world evaluation of the Tandem Diabetes Care t:slim X2 insulin pump with Control-IQ technology in diverse people with T1D. We evaluated glycemic metrics from adults completing the 12-month CLIO study. Participants with ≥75% overall CGM use during this time were included in the analysis. Outcomes were analyzed using a Wilcoxon test. Sample included 1,045 adults (921 Whites, 74 Hispanics, 34 Blacks, 16 Asians) with Black participants reporting the highest baseline HbA1c (median=8% [IQR=7-8.6)) . Glucose Management Indicator (GMI) at study end reflected glycemic improvements for participants with Blacks showing a clinically relevant 0.7% overall reduction (7.3% [6.9-7.6]) (p<0.001) (Figure 1) . Overall, sensor time in range (TIR) at 12 months ranged from 64.9% [56.8-70.5] for Black participants to 72.6% [62.8-80.8] for the White cohort. These findings confirm long-term successful use of Control-IQ technology across diverse ethnicities. Further evaluation of glycemic disparities is recommended to help inform patient support systems. Disclosure R.Graham: Research Support; Tandem Diabetes Care, Inc. E.S.Aronoffspencer: Research Support; Tandem Diabetes Care, Inc. J.E.Pinsker: Employee; Tandem Diabetes Care, Inc., Stock/Shareholder; Tandem Diabetes Care, Inc. S.Habif: Employee; Tandem Diabetes Care, Inc. H.Singh: Employee; Tandem Diabetes Care, Inc. L.Mueller: Employee; Tandem Diabetes Care, Inc., Research Support; Dexcom, Inc., Stock/Shareholder; Tandem Diabetes Care, Inc. M.L.Manning: Employee; Tandem Diabetes Care, Inc. G.Alencar: Employee; Tandem Diabetes Care, Inc. K.N.White: Employee; Tandem Diabetes Care, Inc. A.Wheatcroft: Employee; Tandem Diabetes Care, Inc. K.Carmelo: None. R.Katchalski: Employee; Tandem Diabetes Care, Inc. Funding Tandem Diabetes Care
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call